Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38950 | 1.00 | NNMT (0.44) | NNMTTSHRGRM5SRCUHRF1 | |
| Hydrochloric Acid SCHEMBL21777851 | 0.98 | NNMT (0.42) | NNMTTSHRGRM5SRCUHRF1 | |
| Hydrochloric Acid SCHEMBL31063054 | 0.98 | NNMT (0.42) | NNMTTSHRGRM5SRCUHRF1 | |
| SCHEMBL2608519 | 0.94 | TSHR (0.41) | NNMTTSHRGRM5SRCL3MBTL1 | |
| SCHEMBL30903257 | 0.94 | TSHR (0.41) | NNMTTSHRGRM5SRCL3MBTL1 | |
| SCHEMBL6641301 | 0.89 | NNMT (0.38) | NNMTTSHRGRM5SRCUHRF1 | |
| SCHEMBL29376210 | 0.87 | — | — | |
| SCHEMBL288016 | 0.87 | — | — | |
| SCHEMBL29129603 | 0.83 | NNMT (0.34) | NNMT | |
| SCHEMBL2845218 | 0.79 | CD44 (0.39) | HTR2CHTR2AHTR2BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | claimed |
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2025072206-A1 | INTEGRIN INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | claimed |
| CN-118894816-A | 3, 3-Difluoroallylamine or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2024-11-05 | — | — | CN | claimed |
| CN-111886233-B | Triazolone derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-01-02 | — | — | CN | claimed |
| EP-4534084-A4 | USE OF TETRAHYDRONAPHTHYRIDINE DERIVATIVE FOR PREPARING PRODUCT FOR IMPROVING HYPERPIGMENTATION | SCINNOHUB PHARMACEUTICAL CO LTD (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4713313-A2 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | Springworks Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4713313-A2 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | Springworks Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2026017056-A1 | TETRAHYDRONAPHTHYRIDINE STING INHIBITOR AND PHARMACEUTICAL USE THEREOF | 中国药科大学 | 2026-01-22 | — | — | WO | disclosed |
| EP-4665339-A1 | INHIBITING ALPHA V BETA 8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12497399-B2 | Fluorinated integrin antagonists | OCUTERRA THERAPEUTICS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| WO-2022232838-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022189856-A9 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | ABIONYX PHARMA SA (FR) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022206800-A1 | TETRAHYDRONAPHTHYRIDINE COMPOUND CRYSTAL FORM AND SALT FORM, AND PREPARATION METHODS THEREFOR | 南京明德新药研发有限公司 | 2022-10-06 | — | — | WO | disclosed |
| WO-2022189856-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | ABIONYX PHARMA SA (FR) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022170947-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS KRAS MUTANT G12C INHIBITORS, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 苏州阿尔脉生物科技有限公司 | 2022-08-18 | — | — | WO | disclosed |
| EP-4034236-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | Abionyx Pharma SA (FR) | 2022-08-03 | — | — | EP | disclosed |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3952902-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ITGB6, ITGA6, ITGA2B | NNMT 3458/4885TSHR 1352/4885GRM5 2048/4885 |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | ITGB1, ITGAV, ITGA1 | NNMT 3187/4885TSHR 2159/4885GRM5 601/4885 |
| US-12497399-B2 | Fluorinated integrin antagonists | ITGB5, ITGB1, ITGA5 | NNMT 3420/4885TSHR 474/4885GRM5 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.